HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.

Abstract
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. Its pharmacological profile, including antidiuretic action and receptor binding, was characterized using conscious Brattleboro rats with hereditary diabetes insipidus and Sprague-Dawley rats. In membrane preparations from the liver and kidney, OPC-51803 displaced the [(3)H]AVP binding to V(2)-receptors (K(i) = 49.8 +/- 8.1 nM) more greatly than that to V(1a)-receptors (K(i) = 1061 +/- 60 nM), showing a 21 times higher affinity for V(2)-receptors. At single oral doses of 0.003 to 0.3 mg/kg in female Brattleboro rats, OPC-51803 decreased urine volume (from 10.8 +/- 1.1 to 0.5 +/- 0.2 ml during 0-2 h postdosing) and increased urinary osmolality (from 114 +/- 9 to 432 +/- 114 mOsm/kg) in a dose-dependent manner. During the period of 4-week treatment with OPC-51803, significant and constant antidiuresis was observed. In male Sprague-Dawley rats with normal plasma AVP levels, OPC-51803 at 0.03 to 0.3 mg/kg also produced a dose-dependent antidiuretic action (urine volume: from 2.6 +/- 0.6 to 1.1 +/- 0.2 ml at 0-4 h postdosing). Few changes in urinary parameters, serum parameters, or plasma hormone levels were observed. OPC-51803 did not change blood pressure or heart rate, or inhibit AVP-induced pressor response even at 30 mg/kg p.o. These results demonstrate that OPC-51803 is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. The data suggest that OPC-51803 is a useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of urinary incontinence.
AuthorsS Nakamura, T Hirano, K Tsujimae, M Aoyama, K Kondo, Y Yamamura, T Mori, M Tominaga
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 295 Issue 3 Pg. 1005-11 (Dec 2000) ISSN: 0022-3565 [Print] United States
PMID11082435 (Publication Type: Journal Article)
Chemical References
  • Benzazepines
  • OPC 51803
  • Pyrrolidines
  • Receptors, Vasopressin
  • Arginine Vasopressin
  • Creatinine
Topics
  • Administration, Oral
  • Animals
  • Arginine Vasopressin (metabolism, pharmacology)
  • Benzazepines (administration & dosage, pharmacology)
  • Blood Pressure (drug effects)
  • Creatinine (blood)
  • Diabetes Insipidus (drug therapy)
  • Diuresis (drug effects)
  • Dose-Response Relationship, Drug
  • Female
  • Kidney (metabolism)
  • Liver (metabolism)
  • Male
  • Pyrrolidines (administration & dosage, pharmacology)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Vasopressin (agonists)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: